Where does Noctrix Health, Inc. rank among US patent assignees?

According to USPTO PatentsView (2015–2025 granted utility patents), Noctrix Health, Inc. ranks #23,098 of 49,997 assignees by granted-patent volume, the same sort as the companies listing and top-holders ranking. See /methodology/#corpus-placement.

How many patents does Noctrix Health, Inc. hold?

Noctrix Health, Inc. holds 12 US utility patents granted between 2019 and 2025, spanning 4 technology areas.

What is Noctrix Health, Inc.'s Innovation Score?

Noctrix Health, Inc. has an Innovation Score of 43.9 out of 100 (top 27% of the corpus). This composite metric weighs portfolio volume (40%), grant velocity (20%), technology breadth (25%), and claim depth (15%).

What technology areas does Noctrix Health, Inc. focus on?

Noctrix Health, Inc.'s top technology area is A61N (ELECTROTHERAPY; MAGNETOTHERAPY; Radiation THERAPY; Ultrasound Therapy) with 9 patents, ranking #407 of 1,943 assignees active in that subclass. Grants appear in 4 CPC subclasses total.

Is Noctrix Health, Inc.'s patent grant rate increasing or decreasing?

Noctrix Health, Inc.'s recent grant velocity is +500% compared to the prior five-year period (grant years, not application filing dates). This indicates accelerating grant output.

What does claim depth mean for Noctrix Health, Inc.'s patents?

Noctrix Health, Inc.'s patents average 18.8 claims each. This is an aggregate descriptive count from the grant record; it does not establish claim scope, legal strength, enforceability, or design-around risk.

How is the Noctrix Health, Inc. patent data sourced?

All patent data comes from USPTO PatentsView, a public research dataset maintained by the United States Patent and Trademark Office covering US granted utility patents from 2015 to 2025.

USPTO 2015–2025 USPTO PatentsView US Corporation

Noctrix Health, Inc.

USPTO PatentsView assignee record - 12 granted patents across 4 technology areas, recorded in grant years 2019–2025. Grant-trend analysis is cross-referenced to USPTO Patent Public Search; it does not measure application filings, current R&D, or legal strength. Primary class: A61N (ELECTROTHERAPY; MAGNETOTHERAPY; Radiation THERAPY; Ultrasound Therapy).

Compiled by PlainPatent · May 15, 2026

RSS updates for this company

Explore the portfolio See the ranking

The verdict

According to USPTO PatentsView, Noctrix ranks #23,098 of 49,997 tracked US assignees by granted-patent volume, with 12 patents across 4 technology areas.

#23,098
of 49,997 US assignees by volume: Top 27%
by Innovation Score (43.9/100): 18.8
avg claims per patent: +500%
grant velocity, last 5 yrs

USPTO PatentsView assignee plate

Corpus R23098 · US Corporation #23,098 · 12 grants

GRANTS-MICRO · MID-PACK · PHOTO-FINISH · CPC-NARROW · INNOV-PAR · CLAIMS-RICH · TYPE-USCORP · VEL-SURGE · BOOK-FULL

GRANTS-MICRO 12 grants
MID-PACK #23,098/49,997
PHOTO-FINISH Nishikawa
CPC-NARROW A61N · 4 areas
INNOV-PAR 43.9/100
CLAIMS-RICH 18.8 claims/avg
TYPE-USCORP US Corporation
VEL-SURGE +500% vel
BOOK-FULL 10/10 fields

Nearest grant-volume peer: Nishikawa Co., Ltd. (±0 grants)

Instrument codes from this assignee’s USPTO PatentsView grant sheet: volume band, corpus rank, photo-finish peer, lead CPC, Innovation Score, claim depth, assignee type, velocity, and book completeness. Not a USPTO rating of patent strength.

How Noctrix’s 43.9 Innovation Score adds up

The same four weighted components behind every Innovation Score on PlainPatent: portfolio volume, grant velocity, technology breadth, and claim depth.

Volume 8.9 pts (20%) Velocity 16.7 pts (38%) Breadth 7.1 pts (16%) Claim depth 11.3 pts (26%)

Qualcomm Incorporated · highest

85
Noctrix Health · this assignee

44
3D Lighting… · lowest

7

What this shows Noctrix's Innovation Score is 43.9/100 (top 27% of the PatentsView-derived corpus). The chart places that score against the nearest Innovation Score peers plus corpus poles, not a reprint of the volume ranking.

Does more volume mean deeper claims for Noctrix?

Each dot is one of Noctrix’s 8 nearest volume peers (same corpus rank neighbourhood as the chart above), placed by total granted patents (horizontal) against average claims per patent (vertical). Noctrix’s own 18.8 claims/patent is ABOVE the 10.8 median for these volume peers. More thorough claims than most filers at this scale, not just more of them.

Noctrix vs its 8 nearest volume peers: granted patents vs average claims per patent. Source: USPTO PatentsView.

Where Noctrix's grants concentrate

Noctrix Health, Inc. is a focused PatentsView assignee: 4 CPC subclasses with 75% of grants classified under A61N (ELECTROTHERAPY; MAGNETOTHERAPY; Radiation THERAPY; Ultrasound Therapy). Peak complete grant year is 2022 (2 grants) versus a trough of 1 in 2019. By volume, Noctrix sits between Nishikawa Co., Ltd. and Noul Co, Ltd..

Noctrix's three-year grant acceleration

Noctrix Health, Inc. shows 5 grants in 2022–2024 against only 2 in 2019–2021. That prior window is too thin for a growth multiple (rename and spin-out assignees look artificially high when the baseline is near zero), so PlainPatent withholds a ranked acceleration claim here.

Nishikawa

12
Nisshinbo Brake

12
NLT Spine

12
NLU Products L L C

12
NON Typical

12
Noritake Itron

12
Northvolt AB

12
Noul

12
Noctrix Health ◀

12

What this shows Noctrix holds 12 patents at rank #23,053, shown against the 8 assignees closest to it in grant volume rather than the industry's largest filers.

Companies ranked near Noctrix

By rank, the assignees closest to #23,053 in granted patent volume.

Leaders in A61N (Electrotherapy)

Other assignees with the most granted patents in Noctrix's primary technology class.

Noctrix's Innovation Score vs. every tracked assignee

Composite of portfolio volume, grant velocity, technology breadth, and claim depth (0–100)

44 Top 27% higher than 73% of 49,997 US assignees

Each bar is a band; taller bars hold more US assignees. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count, share, and where it sits relative to this entry.

Source USPTO PatentsView, PlainPatent Innovation Score · 2015–2025

USPTO utility patent grants by year · 2019–2025

Grants by year

Teal-shaded recent years (2020–present) versus the 2019–2019 baseline. Full figures in the table below.

View data table

Noctrix Health, Inc. patent grants by year, 2015–2025
Year	Patents Granted	Share of Period
2019	1	8.3%
2021	1	8.3%
2022	2	16.7%
2023	1	8.3%
2024	2	16.7%
2025partial year	5	41.7%

Which technologies does Noctrix Health, Inc. patent most?

A61N - ELECTROTHERAPY; MAGNETOTHERAPY; Radiation THERAPY; Ultrasound Therapy 9

A61B - DIAGNOSIS; SURGERY; Identification 8

H02J - Circuit Arrangements OR Systems FOR Supplying OR Distributing Electric POWER; Systems FOR Storing Electric Energy 1

A61M - Devices FOR Introducing Media Into, OR Onto, THE Body ; Devices FOR Transducing Body Media OR FOR Taking Media From THE Body ; Devices FOR Producing OR Ending Sleep OR Stupor 1

Top 4 of 4 technology areas

More on this record

Data Source

USPTO PatentsView, US granted patents 2015–2025

View all rankings → How is Innovation Score calculated?

What to do with this data

Noctrix Health, Inc.'s patent record in context - here's where to go next.

Noctrix Health, Inc.'s lead technology class is A61N (ELECTROTHERAPY; MAGNETOTHERAPY; Radiation THERAPY; Ultrasound Therapy), 75% of its portfolio - see every assignee active in that class. Explore A61N
Ranked #23,098 of 49,997 tracked assignees by patent volume - see the full leaderboard. See the ranking
Compare Noctrix Health, Inc. against Nishikawa Co., Ltd., an assignee filing at a similar volume. Compare portfolios
Innovation Score of 43.9/100 blends volume, velocity, technology breadth, and claim depth. How it's calculated

Figures reflect USPTO PatentsView grant data through May 2026; pending applications not yet granted are not counted.

Data sourced from USPTO PatentsView - official U.S. government patent data. See our methodology for computation details. Retrieved and formatted by PlainPatent

Disclaimer: This information is provided for informational purposes only and does not constitute professional advice. Data is sourced from the USPTO PatentsView database. Consult a qualified professional before making decisions based on this data.

Read our methodology - how this data is sourced, computed, and verified.

Data sources used on this page

USPTO PatentsView - the disambiguated bulk patent-grant, assignee, and CPC data this page's figures are derived from. patentsview.org
Cooperative Patent Classification (CPC) - the joint USPTO/EPO classification scheme used to group patents by technology area. cooperativepatentclassification.org
USPTO Patent Public Search - the official interface to verify the status of any individual patent. ppubs.uspto.gov

Compiled by PlainPatent, US Patent Intelligence Editorial Process · May 15, 2026

Every figure on PlainPatent is rendered directly from USPTO source data, no number is typed in by an editor. This page draws directly on USPTO source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of May 2026.